THE WIRE · № 70924
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
01 THE MACHINE READ
WHY IT MATTERS.
Viatris adds marketed non-opioid pain products, shifting its revenue mix toward higher-margin branded medicines.
M&A reshapes Viatris toward branded non-opioid pain
Deal close and integration updates
Integration and commercial execution on acquired products
FULL DISPATCH
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)2026-10-08 12:10 UTC
Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year2026-10-08 12:12 UTC
Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform2026-10-08 12:13 UTC
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder2026-10-08 12:15 UTC
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease2026-10-08 08:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.